Mestag Therapeutics was established in 2020 to develop impactful new medicines for people affected by inflammatory disease and cancer. Recent data point to a type of cells called fibroblasts as being important in driving the disease process.
Our mission is to lead the field in discovering, developing and delivering impactful precision medicines through unparalleled insight into disease-driving fibroblast subpopulations.
We were founded by global thought-leaders in fibroblast biology, united in a common vision of the role of fibroblasts in disease.
Mestag is backed by leading global life sciences & healthcare investors, SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc.
SV Health Investors has over $3 billion in capital commitments raised across ten private venture capital funds and one publicly listed fund. SV has a 25-year track record in the US and Europe with offices in Boston and London. This investment has been committed from SV’s first dedicated biotechnology focussed fund, the Impact Medicine Fund, which invests in precision medicine therapeutics in areas of high unmet need.
JJDC is the strategic venture capital arm of Johnson & Johnson and pursues opportunities to solve critical healthcare needs. Their portfolio companies benefit from the full global capabilities of Johnson & Johnson as they collaborate to drive innovation. JJDC finds transformative ideas and helps them mature into real solutions for today’s patients.